+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The Association Between Attention-Deficit Hyperactivity Disorder, Injuries, and Methylphenidate



The Association Between Attention-Deficit Hyperactivity Disorder, Injuries, and Methylphenidate



Global Pediatric Health 6: 2333794x19845920



Objective. To evaluate the relationship between attention-deficit hyperactivity disorder (ADHD) and injuries and to verify whether methylphenidate (MPH), is associated with decreasing the risk of injuries. Methods. A retrospective cohort study using the computerized database of Maccabi Healthcare Services. The ADHD cohort included all children between 12 and 20 years of age, newly diagnosed with ADHD between 2003 and 2013. The comparison cohort was composed of children who were not diagnosed with ADHD. The primary outcome was traumatic injuries. A Cox proportional hazard regression analysis was conducted to estimate ADHD effects on the risk of injuries. We also conducted a nested case-control study to examine how MPH influences this relationship. Results. A total of 59 798 children were included in the cohort study; 28 921 were classified as exposed (ADHD cohort) and 30 877 were unexposed. The traumatic injuries incidence in the exposed group was significantly higher (adjusted hazard ratio = 1.63 [95% confidence interval = 1.60-1.66]). Similar increased risk was documented also for severe injuries (adjusted hazard ratio = 1.72 [1.59-1.86]). MPH use was significantly associated with 28% lower injury events. Therapy groups were significantly associated with 29% to 40% lower injuries rate for medium- or long-acting MPH. The intensity of therapy was significantly associated with 29% to 33% lower injury rate when the intensity was lower than 0.69 mg/kg/day. Conclusion. Children with ADHD have a 60% increased odds of experiencing an injury. Treatment with MPH reduced the risk by up to 28%. The individual and financial cost secondary to injuries, underscores the public health significance of this problem. Injury prevention should be considered in clinical evaluation of MPH risks and benefits, beyond the conventional consideration of enhancing academic achievements.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066799589

Download citation: RISBibTeXText

PMID: 31106243

DOI: 10.1177/2333794x19845920


Related references

Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type. Neuroscience 167(4): 1183-1191, 2010

No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder. Clinical Neuropharmacology 40(1): 11-15, 2016

Association of the GRIN2B rs2284411 polymorphism with methylphenidate response in attention-deficit/hyperactivity disorder. Journal of Psychopharmacology 31(8): 1070-1077, 2017

Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiology in the Young 22(1): 63-70, 2012

Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B Neuropsychiatric Genetics 147b(8): 1412-1418, 2008

Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder. Behavioral and Brain Functions 6: 57, 2010

Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 147b(8): 1425-1430, 2008

Association of SNAP-25, SLC6A2, and LPHN3 with OROS methylphenidate treatment response in attention-deficit/hyperactivity disorder. Clinical Neuropharmacology 37(5): 136-141, 2015

Association Between 5-HTTLPR Polymorphism and Tics after Treatment with Methylphenidate in Korean Children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology 25(8): 633-640, 2015

Family-based association study of DRD4 gene in methylphenidate-responded Attention Deficit/Hyperactivity Disorder. Plos one 12(3): E0173748, 2017

Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate. Official Gazette of the United States Patent & Trademark Office Patents 1245(1), 2001

Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate. Psychoneuroendocrinology 36(8): 1209-1216, 2011

Association of the catechol-O-methyltransferase polymorphism with methylphenidate response in a classroom setting in children with attention-deficit hyperactivity disorder. International Clinical Psychopharmacology 23(5): 291-298, 2008

Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 35(2): 466-472, 2011

Association of adult attention deficit hyperactivity disorder subtypes and response to methylphenidate HCL treatment: A magnetic resonance spectroscopy study. Neuroscience Letters 604: 188-192, 2015